Norway Flu Diagnostic And Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type Of Flu (Type A, Type B), By Offering (Diagnostics (Rapid Influenza Diagnostic Test, Rapid Molecular Assay, Others), Therapeutics), By Age Group (0-14 Years, 15-64 Years, >=65 Years), And By End-User (Hospital Laboratory, Outpatient Clinic, Reference Laboratory) - Forecasts From 2022 To 2027

  • Published : Aug 2022
  • Report Code : KSI061613357
  • Pages : 75

The Norway flu diagnostic and treatment market is projected to grow at a CAGR of 8.81% throughout the forecast period to reach US$446.611 million in 2027, from US$247.369 million in 2020.

The rising prevalence of influenza is one of the key factors that is projected to bolster the flu diagnostic and treatment market growth in the country during the forecast period. The increasing intensity of the influenza virus during the peak flu seasons is also considered an important factor for the market’s growth in the coming years. According to the latest reports from the Norwegian Institute of Public Health (NIPH), influenza viruses were on the verge of increasing during the flu season.  Furthermore, clinical and lab-verified influenza was present at high levels during February and March of 2019. The NIPH reports, in September 2021, that almost an average of 900 people die in Norway each year as a result of influenza.

The Norway flu diagnostic and treatment market is expected to grow due to the high prevalence of type-A flu, the distribution of vaccines, and others.

The high prevalence of the Type A flu virus during the same period is also one of the major factors which are projected to bolster the flu season and treatment market growth for the type A virus throughout the forecast period. Furthermore, around 870,000 influenza vaccines were distributed in the country, of which more than 700,000 were for people specifically in medical risk groups along with health care personnel who were involved in direct patient care (Source: Norwegian Institute of Public Health (NIPH)). Moreover, the growth in the distribution of the number of influenza vaccines over the past decade further shows the growing prevalence of this disease and is also expected to continue during the coming years, thereby positively impacting the flu diagnostic and treatment market growth in Norway. As per the same source, in 2020-21, 11397 consultations for influenza-like illnesses were recorded. The government is still following the vaccine protocol for influenza to avoid any further outbreaks of the disease.

Product Offerings

  • F. Hoffmann-La Roche Ltd. provides the Cobas® SARS-CoV- 2 and Influenza A & B tests. The company claims that the test kit can differentiate between COVID-19 and Flu. The test only takes 20 mins with minimum cross-contamination and risk of exposure during testing with the closed-system design.
  • Abbott offers the ID NOWTM instrument, which is based on an isothermal system for the rapid and qualitative detection of infectious diseases. The unique ID NOWT technology provides molecular results in minutes, it is based on the technology of isothermal amplification of nucleic acids.

COVID-19 Insights

According to the NIPH report, published in September 2021, COVID-19 has resulted in changes in the healthcare sector in Norway. It caused uncertainties associated with the influenza-like illness data. The report says, during the 2020-21 influenza season, the epidemic limit of influenza-like illness was never crossed.  Throughout the COVID-19 period, the total number of influenza-associated hospitalizations was less than the average number of about 5000 hospitalizations per season. This is the result of social distancing due to COVID-19 protocol, preventing the spread of infectious diseases like influenza. Since the healthcare sector was overburdened with COVID-19 patients, the diagnostics and therapeutics for influenza cases declined to affect the market potential in 2020. Although, post-pandemic the influenza treatment and diagnostic market is expected to grow because of reduced social distancing in Norway.


  • By Type of Flu
    • Type A
    • Type B
  • By Offering
    • Diagnostics
      • Rapid Influenza Diagnostic Test
      • Rapid Molecular Assay
      • Others
    • Therapeutics
  • By Age Group
    • 0-14 Years
    • 15-64 Years
    • >=65 Years
  • By End-User
    • Hospital Laboratory
    • Outpatient Clinic
    • Reference Laboratory

1. Introduction
1.1. Market Definition
1.2. Market Segmentation
2. Research Methodology
2.1. Research Data
2.2. Assumptions
3. Executive Summary
3.1. Research Highlights
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Market Opportunities
4.4. Porters Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitutes
4.4.5. Competitive Rivalry in the Industry
4.5. Product Pipeline
4.6. Industry Value Chain Analysis
5. Norway Flu Diagnostic and Treatment Market Analysis, By Type of Flu
5.1. Introduction
5.2. Type A
5.3. Type B
6. Norway Flu Diagnostic and Treatment Market Analysis, By Offering
6.1. Introduction
6.2. Diagnostics
6.2.1. Rapid Influenza Diagnostic Test
6.2.2. Rapid Molecular Assay
6.2.3. Others
6.3. Therapeutics
7. Norway Flu Diagnostic and Treatment Market Analysis, By Age Group
7.1. Introduction
7.2. 0-14 Years
7.3. 15-64 Years
7.4. >=65 Years
8. Norway Flu Diagnostic and Treatment Market Analysis, By End-User 
8.1. Introduction
8.2. Hospital Laboratory
8.3. Outpatient Clinic
8.4. Reference Laboratory
9. Competitive Environment and Analysis
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. Company Profiles
10.1. F. Hoffmann-La Roche Ltd
10.2. Thermo Fisher Scientific Inc.
10.3. 3M
10.4. Meridian Bioscience

F. Hoffmann-La Roche Ltd

Thermo Fisher Scientific Inc.


Meridian Bioscience

*List is not exhaustive